Abstract

This grant provides the vehicle through which medical, radiation, surgical oncologists and pathologists at the University of California School of Medicine, Davis, and the University of California Davis Medical Center, Sacramento participate in activities of the Northern California Oncology Group, a national cooperative cancer study group. In total, members from some ten departments in the School of Medicine are actively engaged in NCOG activities which include: participation in disease and modality oriented committees, protocol development, patient assessment, protocol entry, pathology review, protocol monitoring, and study publication. It is anticipated that upwards of 100 patients per year will be admitted to NCOG studies from UC Davis. Participation in specific NCOG activities include: 1) case entry for Phase II and III protocols of NCOG, 2) past chairman of the following committees--Chemotherapy, Lung, Gynecology and Hematology, and 3) participation in all specific disease and modality committees of NCOG. Several NCOG protocols, abstracts, and papers have been authored by members of the UCD faculty. In addition, pathologists from UC Davis serve as members of the central pathology review for leukemia, breast cancer and gastrointestinal neoplasms.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA025838-05S1
Application #
3556769
Study Section
Cancer Regional Studies Review Committee (CRS)
Project Start
1983-08-01
Project End
1987-07-31
Budget Start
1985-08-01
Budget End
1987-07-31
Support Year
5
Fiscal Year
1986
Total Cost
Indirect Cost

  Institution

Name
University of California Davis
Department
Type
Schools of Medicine
DUNS #
094878337
City
Davis
State
CA
Country
United States
Zip Code
95618

  Publications

Carlson, R W; Doroshow, J H; Odujinrin, O O et al. (1990) Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. A phase II study of the Northern California Oncology Group. Invest New Drugs 8:387-9
Gandara, D R; Perez, E A; Wold, H et al. (1990) High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology Group. Cancer Chemother Pharmacol 27:243-7
Gandara, D R; Wold, H; Perez, E A et al. (1989) Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen. J Natl Cancer Inst 81:790-4
Torti, F M; Shortliffe, L D; Williams, R D et al. (1988) Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study. J Clin Oncol 6:476-83
Torti, F M; Lum, B L; Aston, D et al. (1987) Superficial bladder cancer: the primacy of grade in the development of invasive disease. J Clin Oncol 5:125-30
Torti, F M; Bristow, M M; Lum, B L et al. (1986) Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res 46:3722-7
Bernstein, J I; Jacobs, C; Meyers, F et al. (1986) A phase II study of cisplatin and cytosine arabinoside for recurrent squamous cell carcinoma of the head and neck. Am J Clin Oncol 9:58-60
Gandara, D R; DeGregorio, M W; Wold, H et al. (1986) High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group Pilot Study in non-small-cell lung cancer. J Clin Oncol 4:1787-93
Meyers, F J; Cardiff, R D; Quadro, R et al. (1986) Epirubicin in non-oat cell lung cancer--response rates and the importance of immunopathology: a Northern California Oncology Group Study. Cancer Treat Rep 70:805-6
Harker, W G; Meyers, F J; Freiha, F S et al. (1985) Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol 3:1463-70

Showing the most recent 10 out of 12 publications